Advisory Board member Ross Camidge comments on his picks for the most exciting lung cancer research being presented at the 2019 ASCO Annual Meeting, including the RELAY trial and the ARROW trial of the RET inhibitor BLU-667 (3:13).

An update was presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, after a median 33.7 months of follow-up.

In the overall cohort, the proportion of patients who received treatment increased significantly from 69.0% in 2011 to 77.2% in 2019, as did the proportion receiving upfront ICI therapy, from 4.7% in 2015 to 45.6% in 2019.

The findings were presented by Ian Davis (Monash University, Melbourne, Victoria, Australia) at the 2022 ASCO Annual Meeting in Chicago, Illinois, USA.

The findings were initially presented at the 2019 ASCO Annual Meeting, and as previously reported by medwireNews , showed comparable progression-free survival (PFS) and overall survival (OS) regardless of whether metformin 2000 mg/day was given alongside chemoradiotherapy and consolidation chemotherapy.

The findings were presented in a poster by Sarah Fleming (Janssen Research & Development, LLC, Raritan, New Jersey, USA) and colleagues at the 2021 ASCO Annual Meeting.

Jonathan Rosenberg video asco CTA At the time of analysis, the median duration of response was not reached, and 53.7% of participants had a response lasting at least 1 year.

These findings follow on from an earlier analysis reported in 2019 and confirm “the importance of complying to international recommendations and give BPA when treating mCRPC patients with bone metastases to prevent skeletal complications,” said Silke Gillessen (Oncology Institute of Southern Switzerland, Bellinzona) at the 2021 ASCO Annual Meeting.

The data from this cohort were reported in JAMA Oncology in 2019 .

These proportions increased to 40% and 58%, respectively, when postapproval QoL publications (to October 2019) were also considered.

Biomarker analyses from the trial – presented at the 2019 ASCO Annual Meeting – provided additional insight into the response elicited by the combination of the PD-L1 inhibitor and VEGF–tyrosine kinase inhibitor.

The EGFR and HER2 inhibitor TAK-788 has antitumor activity against non-small-cell lung cancer with EGFR exon 20 insertions, according to phase I/II findings reported at the 2019 ASCO Annual Meeting.

These findings were presented at the virtual 2020 ASCO Annual Meeting .

Findings for the non-ccRCC patient cohort, updated from an earlier report at ASCO GU 2019 , continue to show “promising antitumor activity” after a median 15.0 months of follow-up, Suárez and team said.

By Shreeya Nanda medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group 2019 ASCO Annual Meeting; Chicago, Illinois, USA: 31 May–4 June ​​​​​​​

Guillermo de Velasco discusses four posters presented at the ESMO Congress 2019 focusing on biomarker analyses of the ADAPTeR, JAVELIN Renal 101 and NIVOREN GETUG-AFU 26 trials (6:07). This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

The efficacy and safety results were presented at the virtual 2020 ASCO Annual Meeting by Elizabeth Plimack, from Fox Chase Cancer Center in Philadelphia, Pennsylvania, USA, and follow on from the interim analysis findings after a minimum of 7 months of follow-up that were presented at ASCO GU 2019.

Neoadjuvant immunotherapy produces encouraging major pathologic response rates among patients with resectable non-small-cell lung cancer, show data presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

Two studies presented at the 2019 ASCO Annual Meeting show a significant progression-free survival, but not overall survival, benefit with the addition of pemetrexed to bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer.